Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ESRRB | O95718 | 1/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28852479 | 0.86 | BCHE (0.71) | BCHEAKR1B1TLR9PDGFRBESR1 | |
| SCHEMBL4124485 | 0.82 | RAB9A (0.62) | BCHETLR9PDGFRBRAB9ANPC1 | |
| SCHEMBL9939626 | 0.81 | CHEK1 (0.63) | CHEK1PDGFRBPDGFRARAB9ANPC1 | |
| SCHEMBL28044781 | 0.80 | TLR9 (0.62) | BCHETLR9ESR1ESR2RAB9A | |
| SCHEMBL9939079 | 0.79 | CA12 (0.46) | CHEK1AKR1B1ESR2RAB9ANPC1 | |
| SCHEMBL1289517 | 0.79 | ESR1 (0.73) | CHEK1ESR1ESR2POLBESRRB | |
| SCHEMBL9939279 | 0.78 | CHEK1 (0.46) | CHEK1PDGFRBPDGFRAESR1ESR2 | |
| SCHEMBL9939727 | 0.78 | ESR2 (0.73) | CHEK1PDGFRBPDGFRAESR2RAB9A | |
| SCHEMBL397896 | 0.76 | NPC1 (0.67) | TLR9PDGFRBRAB9ANPC1MAPT | |
| SCHEMBL1289597 | 0.75 | ESR1 (0.55) | ESR1ESR2POLBESRRBESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-09-29 | — | — | US | claimed |
| US-9364481-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20160067254-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-03-10 | — | — | US | claimed |
| US-9012646-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-04-21 | — | — | US | claimed |
| US-20140329821-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2014-11-06 | — | — | US | claimed |
| US-8785643-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | claimed |
| EP-2651223-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2013-10-03 | — | — | US | claimed |
| WO-2012083165-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | claimed |
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-09-29 | — | — | US | disclosed |
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-09-29 | — | — | US | disclosed |
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-09-29 | — | — | US | disclosed |
| US-9364481-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9364481-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2651223-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2013-10-03 | — | — | US | disclosed |
| WO-2012083165-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083165-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | CHEK1 3857/4885BCHE 2234/4885AKR1B1 17/4885 |
| US-20140329821-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | CHEK1 3857/4885BCHE 2234/4885AKR1B1 17/4885 |
| US-20160067254-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | CHEK1 3857/4885BCHE 2234/4885AKR1B1 17/4885 |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | CHEK1 3857/4885BCHE 2234/4885AKR1B1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.